Friedlaender, A. et al. 2020. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. Acta Oncologica. 59, 9 (Sep. 2020), 1058–1063. DOI:https://doi.org/10.1080/0284186X.2020.1781249.